Risk factors for neonatal morbidity and mortality among "healthy," late preterm newborns

Carrie K Shapiro-Mendoza1, Kay M Tomashek, Milton Kotelchuck

  • 1Centers for Disease Control and Prevention, Division of Reproductive Health, Maternal and Infant Health Branch, Atlanta, GA 30341, USA. ayn9@cdc.gov

Insights

Limited research exists on late preterm infants. This study identified risk factors for neonatal morbidity in healthy late preterm infants, aiding targeted monitoring and improved outcomes.

Area of Science:

  • Neonatology
  • Public Health
  • Perinatal Epidemiology

Background:

  • Research on neonatal outcomes for late preterm infants (34-36 weeks gestation) is limited.
  • Identifying at-risk late preterm infants is crucial for improving health and reducing costs.

Purpose of the Study:

  • To investigate neonatal morbidity risk factors in "healthy," singleton, late preterm infants.
  • To inform strategies for closer monitoring and earlier follow-up for at-risk infants.

Main Methods:

  • Population-based cohort study of "healthy," singleton, late preterm infants born in Massachusetts (1998-2002).
  • Comparison of neonatal morbidity incidence (readmissions, observational stays, mortality) using adjusted risk ratios.
  • Analysis included infant, obstetric, and sociodemographic factors.

Main Results:

  • Among 9552 infants, 4.8% experienced readmission and 1.3% had observational stays.
  • Risk factors for morbidity included being firstborn, breastfeeding at discharge, labor/delivery complications, public payer source, and Asian/Pacific Islander mother.
  • Non-Hispanic Black infants showed a decreased risk for neonatal morbidity.

Conclusions:

  • Specific infant, obstetric, and sociodemographic factors are associated with neonatal morbidity in "healthy" late preterm infants.
  • Identifying these risk factors enables targeted interventions and improved post-discharge care.
  • This knowledge can enhance health outcomes and potentially reduce healthcare expenditures.

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...